Compare Koninklijke Philips NV (PHG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs Summit Therapeutics Inc — how do they compare? Koninklijke Philips NV trades at $24.94 (market cap $24.84B), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: Koninklijke Philips NV is the larger of the two by market cap, and Koninklijke Philips NV pays a 4.01% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PHG | SMMT | |
|---|---|---|
Market Cap | $24.84B | $13.79B |
Sector | Health | Health |
52-Week High | $32.91 | $26.38 |
52-Week Low | $25.02 | $12.43 |
Enterprise Value | $31.44B | $13.11B |
Dividend Yield | 4.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $25.29, down 2.32% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $0.57 beating expectations of $0.40, and positive net income of $895M in 2025 reversing previous losses. Recent product launches in women's health and AI-powered medical devices demonstrate innovation momentum.
The outlook is mixed with strong fundamentals and analyst support (36% buy ratings) offset by technical weakness. Key opportunities include margin expansion and new product adoption, while risks involve cybersecurity threats and competitive pressures in healthcare technology.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
